---
title: "Mutation Analysis of Various Cancer Types"
format: 
  revealjs:
    css: styles.css
    slide-number: true
    width: 1600  # Wider format helps with side-by-side plots
    height: 900
    theme: simple
    transition: fade
    smaller: true # Automatically shrinks text slightly to fit
    scrollable: true # Allows scrolling if content is too long
    embed-resources: true
---

## Introduction/Background

-   **Study Cohort:** 1661 patients/samples.
-   **Objective:** Identify predictive biomarkers for Immune Checkpoint Inhibitors (ICI).
-   **Hypothesis:** Does Tumor Mutational Burden (TMB) correlate with survival?
    -   *Concept:* Higher TMB $\rightarrow$ Higher response?

![](../results/figures/Figure_paper.png){width=60%}

*From Samstein et al., Nat Genet 2019*

## Materials

::: columns
::: {.column width="50%"}
-   **Sequencing:** MSK-IMPACT (Next Generation Sequencing).
-   **Panels Used:**
    -   IMPACT 3 (341 genes)
    -   IMPACT 5 (410 genes)
    -   IMPACT 6 (468 genes)
-   **Note:** Higher mutation counts detected as more genes are analyzed.

-   **Datasets:**
    -   data_clinical_patient.txt
    -   data_clinical_sample.txt
    -   data_gene_panel_matrix.txt
    -   data_mutations.txt
    -   data_sv.txt
:::

::: {.column width="50%"}
![](../results/figures/mutation_count_IMPACT.png)
:::
:::

## Methods

::: columns
  
::: {.column width="31%"}

### Survival Analysis
-   **Package:** `survival`
-   **Function:** `Surv()`
    -   Parameters: Survival time + Status (0=Living, 1=Deceased).
-   **Estimator:** `survfit()` (Kaplan-Meier).
-   **Data:** `clinical_patients`.
-   **Output:** Step curve stratified by parameters (sex, age, cancer type).

:::
  
::: {.column width="31%"}
### Cox Regression
-   **Package:** `survival`
-   **Goal:** Hazard risk study.
-   **Formula:** $\lambda(t,j) = \lambda_0(t) \cdot \exp(\sum \beta_i X_i)$
    -   $\lambda$: Survival probability for individual $j$ at time $t$.
    -   $X_i$: Explanatory variables.
-   **Hazard Ratio:** $\displaystyle \frac{\lambda(t,j_1)}{\lambda(t,j_2)} = \exp(\beta_i)$

:::

::: {.column width="31%"}
### GSEA
-   **Gene Set Enrichment Analysis**
-   **Source:** GO Data from Molecular Signature Database.
-   **Metric:** Ranked list based on numbers of mutated Samples per Gene.
-   **Function:** `fgseaMultilevel()` from `fgsea` package.

:::

:::

## Results: Overview - Survival Analysis & Mutation Types

::: {layout-ncol=3}
![](../results/figures/surv_count_per_gender_per_cancer.png)

![](../results/figures/survival_cancer_type.png)

::: {width="90%"}

![](../results/figures/SV_count_per_cancer.png)


![](../results/figures/mutation_by_cancer.png)
:::

:::

## Results: Structural Variants (SV)

**Structural Variants (SVs) are large-scale genomic rearrangements that can significantly disrupt gene function.**

::: columns
::: {.column width="50%"}

![](../results/figures/SV_lengths_distribution.png)
:::

::: {.column width="50%"}

![](../results/figures/SV_count_per_gene.png)
:::
:::

**EGFR is the most significantly overrepresented gene when aggregating both the beginning and ending sites of the SVs.**

## Results: EGFR Focus in Glioma  


**EGFR is a receptor tyrosine kinase frequently altered in cancer. Its activation drives uncontrolled cell growth and proliferation.** ^\*^


::: columns
  
::: {.column width="50%"}


![](../results/figures/EGFR_count_per_cancer.png){width=100%}
:::

::: {.column width="50%"}

![](../results/figures/SV_gene_in_glioma.png){width=100%}
:::

:::

\* *From Yarden & Sliwkowski, Nat Rev Mol Cell Biol 2001*

## Results: Mutations in Glioma

::: columns

::: {.column width="60%"}



![](../results/figures/Mutation_count_in_glioma.png){width=100%}
:::

::: {.column width="40%"}

- **EGFR is not a primary mutational target**   



- **Alternative Pathways:** Genes like **TERT** and **TP53** show a much higher incidence of pinpoint mutations. 

  â†’ distinct biological pathways compared to the SV-driven EGFR pathway.


:::

:::

## Results: GSEA (SV & Mutations)

**Significant Pathways in Glioma**

::: table-small
| Biological Process | pvalue | adjusted pvalue |
|:---|---:|---:|
| [GOBP_CIRCULATORY_SYSTEM_DEVELOPMENT]{style="color: red;"} | 1.87e-06 | 0.00018 |
| GOBP_NEGATIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS | 3.91e-07 | 0.00018 |
| [GOBP_REGULATION_OF_APOPTOTIC_SIGNALING_PATHWAY]{style="color: green;"} | 8.07e-07 | 0.00018 |
| GOBP_REGULATION_OF_CELLULAR_LOCALIZATION | 1.65e-06 | 0.00018 |
| [GOBP_REGULATION_OF_MITOTIC_CELL_CYCLE_PHASE_TRANSITION]{style="color: blue;"} | 1.38e-06 | 0.00018 |
| [GOBP_TUBE_DEVELOPMENT]{style="color: red;"} | 3.69e-06 | 0.00030 |
| GOBP_CELLULAR_RESPONSE_TO_OXYGEN_LEVELS | 7.12e-06 | 0.00039 |
| [GOBP_CELL_CYCLE_G1_S_PHASE_TRANSITION]{style="color: blue;"} | 6.76e-06 | 0.00039 |
| [GOBP_REGULATION_OF_CELL_CYCLE_G1_S_PHASE_TRANSITION]{style="color: blue;"} | 6.40e-06 | 0.00039 |
| [GOBP_MITOTIC_CELL_CYCLE_PHASE_TRANSITION]{style="color: blue;"} | 8.29e-06 | 0.00040 |
| [GOBP_BLOOD_VESSEL_MORPHOGENESIS]{style="color: red;"} | 1.71e-05 | 0.00070 |
| [GOBP_REGULATION_OF_EXTRINSIC_APOPTOTIC_SIGNALING_PATHWAY]{style="color: green;"} | 1.58e-05 | 0.00070 |
| [GOBP_APOPTOTIC_SIGNALING_PATHWAY]{style="color: green;"} | 2.78e-05 | 0.00105 |
| GOBP_CELL_AGING | 3.01e-05 | 0.00106 |
| [GOBP_EXTRINSIC_APOPTOTIC_SIGNALING_PATHWAY]{style="color: green;"} | 3.40e-05 | 0.00112 |
:::

## Results: Confounders in Glioma

::: {.panel-tabset}

### Gender Effect (Global)
![](../results/figures/surv_plot_per_gender.png){width=60%}

### Glioma Subset (KM)
![](../results/figures/survival_glioma_gender.png){width=60%}

### Glioma Subset (Adjusted)
![](../results/figures/surv_plot_per_gender_for_glioma.png){width=60%}

:::



## Discussion

::: columns

::: {.column width="50%"}

-   **Tumor Burden Hypothesis:**
    -   General trend: Higher TMB $\rightarrow$ higher survival.
    
-   **Severity Indication:**
    -   Surprisingly, more mutations do not necessarily indicate a higher severity of cancer in terms of immediate survival.

-   **The Glioma Exception:**
    -   Glioma appears to be an exemption to the TMB rule.
    -   No clear correlation observed in our subset analysis.

:::

::: {.column width="50%"}

![](../results/figures/TMB_all_vs_glioma.png)
:::

:::
